Leucine-rich repeat kinase 2 (LRRK2; Dardarin) inhibitors have been detailed in a recent Merck Sharp & Dohme Corp. patent and reported to be useful for the treatment of Parkinson’s disease, among others.
Crinetics Pharmaceuticals Inc. has reported parathyroid hormone PTH1 receptor antagonists potentially useful for the treatment of kidney stones, osteoporosis, cardiovascular disorders, cognitive disorders, primary hyperparathyroidism and secondary hyperparathyroidism.
Research at Incyte Corp. has led to the development of pyrazoloquinoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors and reported to be useful for the treatment of cancer, inflammatory and immunological disorders.
Viva Star Biosciences (Suzhou) Co. Ltd. has identified substituted sulfonylurea compounds acting as NLRP3 inflammasome inhibitors and reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s and Parkinson’s disease.
Son of sevenless homolog 1 (SOS1) inhibitors have been detailed in a Shanghai Allist Pharmaceuticals Co. Ltd. patent and described as useful for the treatment of cancer, arteriovenous malformations, cardiofaciocutaneous syndrome, Costello syndrome, Legius syndrome (neurofibromatosis type 1-like syndrome), neurofibromatosis type 1, Noonan syndrome and Splenomegaly, among others.
Research at Boehringer Ingelheim Pharma GmbH & Co. KG has led to the development of proteolysis targeting chimeras (PROTACs) comprising a Von Hippel-Lindau E3 ubiquitin ligase (VHL)-binding moiety covalently linked to probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) and/or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker.
A Blacksmith Medicines Inc. patent describes the development of prodrugs of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors reported to be useful for the treatment of complicated urinary tract infections (UTIs).
Turbinmicin analogues reported to be useful for the treatment of fungal infections have been described in a recent Wisconsin Alumni Research Foundation (WARF) patent.
RSS